Transplanting animal organs into humans is an attractive approach, but the risk of immune rejection or catching a virus from the organ has been a significant roadblock. eGenesis used CRISPR to address the latter concern.
Scientists from China, South Korea and the U.S. succeeded in safe correction of the gene mutation in early human embryos that results in hypertrophic cardiomyopathy by using CRISPR/Cas9 genome editing technique.